


Company registration number: 04933728

**A.F.M. Complementary Therapies Ltd  
Trading as A.F.M. Complementary Therapies Ltd**

**Unaudited financial statements**

**5 April 2017**

WEDNESDAY



\*A6AIVVIK\*

A10

12/07/2017

#378

COMPANIES HOUSE

## **A.F.M. Complementary Therapies Ltd**

### **Contents**

	<b>Page</b>
Directors and other information	<b>2</b>
Directors report	<b>3</b>
Statement of comprehensive income	<b>4</b>
Statement of financial position	<b>5 - 6</b>
Statement of changes in equity	<b>7</b>
Notes to the financial statements	<b>8 - 12</b>

**A.F.M. Complementary Therapies Ltd**

**Directors and other information**

<b>Directors</b>	Mrs Anne Mansbridge
<b>Secretary</b>	Mr R Morris
<b>Company number</b>	04933728
<b>Registered office</b>	Unit 20 Hopewell Business Centre 105 Hopewell Drive Chatham Kent ME5 7DX
<b>Business address</b>	53 Marshall Grove South Lanarkshire Hamilton ML3 8NL

**A.F.M. Complementary Therapies Ltd**

**Directors report  
Year ended 5 April 2017**

The directors present their report and the unaudited financial statements of the company for the year ended 5 April 2017.

**Directors**

The directors who served the company during the year were as follows:


Mrs Anne Mansbridge

**Small company provisions**

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

This report was approved by the board of directors on 22 June 2017 and signed on behalf of the board by:

Mrs Anne Mansbridge  
Director

A handwritten signature in black ink, appearing to read 'Anne Mansbridge', written in a cursive style.

**A.F.M. Complementary Therapies Ltd**

**Statement of comprehensive income  
Year ended 5 April 2017**

	<b>Note</b>	<b>2017 £</b>	<b>2016 £</b>
<b>Turnover</b>		14,449	15,608
<b>Cost of sales</b>		(541)	(887)
<b>Gross profit</b>		<u>13,908</u>	<u>14,721</u>
<b>Administrative expenses</b>		(15,137)	(14,297)
<b>Operating (loss)/profit</b>		<u>(1,229)</u>	<u>424</u>
<b>(Loss)/profit before taxation</b>	<b>5</b>	<u>(1,229)</u>	<u>424</u>
<b>Tax on (loss)/profit</b>		<u>-</u>	<u>-</u>
<b>(Loss)/profit for the financial year and total comprehensive income</b>		<u><u>(1,229)</u></u>	<u><u>424</u></u>

All the activities of the company are from continuing operations.

The notes on pages 8 to 12 form part of these financial statements.

**A.F.M. Complementary Therapies Ltd**

**Statement of financial position  
5 April 2017**

	Note	2017 £	£	2016 £	£
<b>Fixed assets</b>					
Intangible assets	6	7,350		8,400	
			7,350		8,400
<b>Current assets</b>					
Cash at bank and in hand		2,431		3,110	
		2,431		3,110	
<b>Creditors: amounts falling due within one year</b>	8	(600)		(600)	
<b>Net current assets</b>			1,831		2,510
<b>Total assets less current liabilities</b>			9,181		10,910
<b>Net assets</b>			9,181		10,910
<b>Capital and reserves</b>					
Called up share capital			2		2
Profit and loss account			9,179		10,908
<b>Shareholders funds</b>			9,181		10,910

For the year ending 5 April 2017 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

**Directors responsibilities:**

- The shareholders have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.


**The notes on pages 8 to 12 form part of these financial statements.**

**A.F.M. Complementary Therapies Ltd**

**Statement of financial position (continued)**  
**5 April 2017**

These financial statements were approved by the board of directors and authorised for issue on 22 June 2017, and are signed on behalf of the board by:

Mrs Anne Mansbridge  
Director

A handwritten signature in black ink, reading "Anne Frances Mansbridge". The signature is written in a cursive style with a large initial 'A'.

Company registration number: 04933728

**The notes on pages 8 to 12 form part of these financial statements.**

**A.F.M. Complementary Therapies Ltd**

**Statement of changes in equity  
Year ended 5 April 2017**

	Called up share capital £	Profit and loss account £	<b>Total £</b>
<b>At 6 April 2015</b>	2	11,584	11,586
(Loss)/profit for the year	<u>          </u>	424	<u>424</u>
<b>Total comprehensive income for the year</b>	-	424	424
Dividends paid and payable	<u>          </u>	(1,100)	<u>(1,100)</u>
<b>Total investments by and distributions to owners</b>	-	(1,100)	(1,100)
<b>At 5 April 2016 and 6 April 2016</b>	<u>2</u>	<u>10,908</u>	<u>10,910</u>
(Loss)/profit for the year	<u>          </u>	(1,229)	<u>(1,229)</u>
<b>Total comprehensive income for the year</b>	-	(1,229)	(1,229)
Dividends paid and payable	<u>          </u>	(500)	<u>(500)</u>
<b>Total investments by and distributions to owners</b>	-	(500)	(500)
<b>At 5 April 2017</b>	<u><u>2</u></u>	<u><u>9,179</u></u>	<u><u>9,181</u></u>



## **A.F.M. Complementary Therapies Ltd**

### **Notes to the financial statements Year ended 5 April 2017**

#### **1. General information**

The company is a private company limited by shares, registered in England. The address of the registered office is Unit 20, Hopewell Business Centre, 105 Hopewell Drive, Chatham Kent, ME5 7DX.

#### **2. Statement of compliance**

These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

#### **3. Accounting policies**

##### **Basis of preparation**

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in sterling, which is the functional currency of the entity.

##### **Transition to FRS 102**

The entity transitioned from previous UK GAAP to FRS 102 as at 6 April 2015. Details of how FRS 102 has affected the reported financial position and financial performance is given in note 9.

##### **Turnover**

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer, usually on despatch of the goods; the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

##### **Taxation**

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively.

Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

##### **Goodwill**

Goodwill arises on business acquisitions and represents the excess of the cost of the acquisition over the company's interest in the net amount of the identifiable assets, liabilities and contingent liabilities of the acquired business.

Goodwill is measured at cost less accumulated amortisation and accumulated impairment losses. It is amortised on a straight line basis over its useful life. Where a reliable estimate of the useful life of goodwill or intangible assets cannot be made, the life is presumed not to exceed five years.

**A.F.M. Complementary Therapies Ltd**

**Notes to the financial statements (continued)**  
**Year ended 5 April 2017**

**Amortisation**

Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:

If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.

**Tangible assets**

Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses.

Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.

**Depreciation**

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

**Impairment**

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.

For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.

## A.F.M. Complementary Therapies Ltd

### Notes to the financial statements (continued) Year ended 5 April 2017

#### Financial instruments

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Debt instruments are subsequently measured at amortised cost.

Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment.

Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics.

Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

#### 4. Staff costs

The average number of persons employed by the company during the year, including the directors was 1 (2016: 1).

#### 5. Loss/profit before taxation

Loss/profit before taxation is stated after charging/(crediting):

	2017	2016
	£	£
Amortisation of intangible assets	1,050	1,050
Depreciation of tangible assets	359	-

**A.F.M. Complementary Therapies Ltd**

**Notes to the financial statements (continued)**  
**Year ended 5 April 2017**

**6. Intangible assets**

	<b>Goodwill</b>	<b>Total</b>
	<b>£</b>	<b>£</b>
<b>Cost</b>		
At 6 April 2016 and 5 April 2017	<u>21,000</u>	<u>21,000</u>
<b>Amortisation</b>		
At 6 April 2016	12,600	12,600
Charge for the year	<u>1,050</u>	<u>1,050</u>
<b>At 5 April 2017</b>	<u>13,650</u>	<u>13,650</u>
<b>Carrying amount</b>		
At 5 April 2017	<u>7,350</u>	<u>7,350</u>
At 5 April 2016	<u>8,400</u>	<u>8,400</u>

**7. Tangible assets**

	<b>Fixtures, fittings and equipment £</b>	<b>Total  £</b>
<b>Cost</b>		
At 6 April 2016	1,468	1,468
Additions	<u>359</u>	<u>359</u>
<b>At 5 April 2017</b>	<u>1,827</u>	<u>1,827</u>
<b>Depreciation</b>		
At 6 April 2016	1,468	1,468
Charge for the year	<u>359</u>	<u>359</u>
<b>At 5 April 2017</b>	<u>1,827</u>	<u>1,827</u>
<b>Carrying amount</b>		
At 5 April 2017	<u>-</u>	<u>-</u>
At 5 April 2016	<u>-</u>	<u>-</u>

**8. Creditors: amounts falling due within one year**

	<b>2017</b>	<b>2016</b>
	<b>£</b>	<b>£</b>
Other creditors	<u>600</u>	<u>600</u>

**A.F.M. Complementary Therapies Ltd**

**Notes to the financial statements (continued)**  
**Year ended 5 April 2017**

**9. Transition to FRS 102**

These are the first financial statements that comply with FRS 102. The company transitioned to FRS 102 on 6 April 2015.

**Reconciliation of equity**

No transitional adjustments were required.

**Reconciliation of profit or loss for the year**

No transitional adjustments were required.